NCT04239989View on ClinicalTrials.gov

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Bronchiolitis Obliterans

Interventions

DRUG

Itacitinib

Given PO

DRUG

Itacitinib Adipate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER